Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00

Hims & Hers Health (NYSE:HIMS) had its target price hoisted by Citigroup from $25.00 to $27.00 in a report issued on Tuesday morning,Benzinga reports. Citigroup currently has a sell rating on the stock.

HIMS has been the subject of several other research reports. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America raised their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research note on Thursday, February 20th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Finally, Canaccord Genuity Group boosted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $35.71.

Hims & Hers Health Trading Down 1.4 %

Hims & Hers Health stock opened at $41.30 on Tuesday. The stock has a 50 day moving average of $36.19 and a two-hundred day moving average of $26.46. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a market capitalization of $9.02 billion, a price-to-earnings ratio of 93.85 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Equities analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares in the company, valued at $4,712,033.25. The trade was a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 33,513 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $1,118,296.76. This trade represents a 50.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock worth $38,080,320 over the last ninety days. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. grew its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter worth about $38,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.